BR112022021758A2 - Proteína e vacina contra infecção pelo sars-cov-2 - Google Patents

Proteína e vacina contra infecção pelo sars-cov-2

Info

Publication number
BR112022021758A2
BR112022021758A2 BR112022021758A BR112022021758A BR112022021758A2 BR 112022021758 A2 BR112022021758 A2 BR 112022021758A2 BR 112022021758 A BR112022021758 A BR 112022021758A BR 112022021758 A BR112022021758 A BR 112022021758A BR 112022021758 A2 BR112022021758 A2 BR 112022021758A2
Authority
BR
Brazil
Prior art keywords
cov
protein
infection
sars
vaccine against
Prior art date
Application number
BR112022021758A
Other languages
English (en)
Inventor
Wei Xiawei
Lu Guangwen
Wang Wei
Yang Jinliang
Yang Li
Li Jiong
Yang Jingyun
Wei Yuquan
Wang Zhenling
Zhao Zhiwei
Shen Guobo
Original Assignee
Westvac Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westvac Biopharma Co Ltd filed Critical Westvac Biopharma Co Ltd
Publication of BR112022021758A2 publication Critical patent/BR112022021758A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

PROTEÍNA E VACINA CONTRA INFECÇÃO PELO SARS-COV-2. Uma proteína e vacina de infecção anti-SARS-CoV-2. A proteína contém um domínio estrutural ligado a um receptor da enzima conversora de angiotensina 2 em uma proteína S do SARS-CoV-2. Uma vacina para prevenir e/ou tratar a infecção por SARS-CoV-2 contendo a proteína de infecção anti-SARS-CoV-2 e materiais auxiliares ou componentes auxiliares farmaceuticamente aceitáveis.
BR112022021758A 2020-02-24 2020-09-18 Proteína e vacina contra infecção pelo sars-cov-2 BR112022021758A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010113054 2020-02-24
PCT/CN2020/116109 WO2021169255A1 (zh) 2020-02-24 2020-09-18 抗SARS-CoV-2感染的蛋白及疫苗

Publications (1)

Publication Number Publication Date
BR112022021758A2 true BR112022021758A2 (pt) 2023-01-17

Family

ID=74483437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021758A BR112022021758A2 (pt) 2020-02-24 2020-09-18 Proteína e vacina contra infecção pelo sars-cov-2

Country Status (8)

Country Link
US (1) US20230233665A1 (pt)
EP (1) EP4112648A4 (pt)
JP (1) JP7464789B2 (pt)
CN (1) CN112300251B (pt)
BR (1) BR112022021758A2 (pt)
CA (1) CA3186989A1 (pt)
WO (1) WO2021169255A1 (pt)
ZA (1) ZA202213710B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
WO2021222988A1 (en) * 2020-05-07 2021-11-11 Griffith University Cell entry-modulating agents and uses therefor
WO2022013609A1 (en) * 2020-07-13 2022-01-20 Immunovaccine Technologies, Inc. Sars-cov-2 vaccine compositions and methods of preparation and use
KR20230164648A (ko) 2020-12-22 2023-12-04 큐어백 에스이 SARS-CoV-2 변이체에 대한 RNA 백신
CN112851824A (zh) * 2021-02-09 2021-05-28 浙江大学 一种融合蛋白及其在制备新型冠状病毒亚单位疫苗中的应用
CN112940138A (zh) * 2021-02-10 2021-06-11 军事科学院军事医学研究院军事兽医研究所 三聚体化新冠病毒受体结合域、其制备方法与应用
EP4291212A1 (en) * 2021-02-15 2023-12-20 LivingMed Biotech S.R.L. Genetically clostridium modifiedstrains expressing recombinant antigens and uses thereof
WO2022178545A1 (en) * 2021-02-19 2022-08-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Novel compositions of matter comprising stabilized coronavirus antigens and their use
CN112940086B (zh) * 2021-02-26 2022-06-03 深圳市亚辉龙生物科技股份有限公司 新型冠状病毒抗原及其应用
CN114456241B (zh) * 2021-03-01 2023-11-21 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的蛋白及疫苗
CN112941091A (zh) * 2021-03-17 2021-06-11 吉林大学 一种猪血凝性脑脊髓炎dna疫苗及其制备方法
MX2021003199A (es) * 2021-03-18 2022-09-19 Centro De Investig Y De Estudios Avanzados Del I P N Vacunas para prevenir la covid19 basadas en sitios no glicosilados del dominio de union al receptor (rbd) de la proteina s del virus sars-cov-2.
CN113150085B (zh) * 2021-04-27 2023-04-18 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的组合物
CN115340998B (zh) * 2021-05-14 2023-12-01 上海科技大学 一种重组病毒载体、包含其的重组病毒、新冠病毒疫苗及其应用
WO2022254459A1 (en) * 2021-05-31 2022-12-08 Bharat Biotech International Limited Adjuvanted inactivated recombinant rabies virus vectored coronavirus vaccine formulations
CN113444156B (zh) * 2021-06-07 2022-06-24 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 新型冠状病毒肺炎重组人5型腺病毒疫苗
AR123532A1 (es) * 2021-09-16 2022-12-14 Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos
WO2023073672A1 (en) * 2021-10-29 2023-05-04 Geneone Life Science, Inc. Therapeutic and vaccine candidates against sars-cov-2
CN114150005B (zh) * 2022-02-09 2022-04-22 广州恩宝生物医药科技有限公司 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗
CN114740199A (zh) * 2022-03-18 2022-07-12 北京安奇生物医药科技有限公司 一种SARS-CoV-2中和抗体试剂盒及其应用
CN115074373A (zh) * 2022-06-24 2022-09-20 岳阳新华达制药有限公司 一种新冠病毒rbd蛋白的制备方法及其在疫苗中的应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024008014A1 (zh) * 2022-07-07 2024-01-11 成都威斯克生物医药有限公司 抗SARS-CoV-2或其突变体感染的药物组合物及其联合用药物
CN117003835A (zh) * 2023-03-17 2023-11-07 成都威斯克生物医药有限公司 抗SARS-CoV-2奥密克戎突变株XBB及其亚型感染的蛋白及疫苗

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL207933B1 (pl) * 2001-05-17 2011-02-28 Stichting Tech Wetenschapp Wyizolowana lub zrekombinowana replikatywna cząsteczka podobna do koronawirusa, kompozycja zawierająca tą cząsteczkę do zastosowania terapeutycznego, do zastosowania jako immunogen lub szczepionka i do zastosowania diagnostycznego
CN1918288A (zh) * 2003-06-20 2007-02-21 蛋白质科学公司 表达sars免疫原的载体、含所述载体或其表达产物的组合物、制备和使用方法和实验
CN1852921A (zh) 2003-07-21 2006-10-25 美国政府卫生及公众服务部国家卫生协会 Sars冠状病毒刺突糖蛋白的可溶性片段
US20050113298A1 (en) 2003-09-15 2005-05-26 The Brigham And Women's Hospital, Inc. Receptor binding peptides derived from the SARS S protein
US20050282154A1 (en) 2003-10-06 2005-12-22 The Brigham And Women's Hospital, Inc. Angiotensin-converting enzyme-2 as a receptor for the SARS coronavirus
CN1258538C (zh) * 2003-12-23 2006-06-07 北京大学 一种重组蛋白
CN1884303A (zh) * 2005-06-20 2006-12-27 中国医学科学院基础医学研究所 SARS－CoV病毒结构蛋白的融合蛋白及其高量表达与纯化和用途
CN100519583C (zh) * 2005-08-10 2009-07-29 中国科学院上海生命科学研究院 Sars中和性抗体及应用
CN103554244B (zh) * 2013-05-09 2016-09-07 香雪集团(香港)有限公司 具有抑制呼吸道病毒感染的活性的肽及其应用和制备方法
CN105934441A (zh) * 2013-11-26 2016-09-07 贝勒医学院 新型sars免疫原性组合物
WO2015143335A1 (en) * 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
KR20170140180A (ko) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
WO2017020570A1 (en) * 2015-08-06 2017-02-09 Medigen Biotechnology Corp. Virus-like particle vaccines
US10676511B2 (en) 2015-09-17 2020-06-09 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
EP3601367A4 (en) * 2017-03-30 2020-09-16 The University of Queensland CHEMERICAL MOLECULES AND ASSOCIATED USES
CN109182380B (zh) * 2018-08-14 2022-06-03 浙江大学 杆状病毒表达的猪瘟e2亚单位疫苗的制备方法及应用
CN111592602B (zh) * 2020-02-10 2021-03-02 中国科学院微生物研究所 一种β冠状病毒抗原、其制备方法和应用
BR102021003012A2 (pt) * 2020-02-19 2021-11-30 Univ Berlin Charite Métodos para o diagnóstico de infecção por sars-cov-2, kit e usos
CN111375055B (zh) * 2020-02-20 2021-09-03 陈宛莎 一种2019-nCoV亚单位疫苗组合物及其免疫方法
CN112079907B (zh) 2020-09-22 2022-03-29 上海捷门生物技术有限公司 一种重组新型冠状病毒covid-19 s-rbd蛋白及其制备方法和应用

Also Published As

Publication number Publication date
EP4112648A4 (en) 2023-10-11
CN112300251A (zh) 2021-02-02
CA3186989A1 (en) 2021-09-02
CN112300251B (zh) 2022-04-05
WO2021169255A1 (zh) 2021-09-02
JP7464789B2 (ja) 2024-04-09
ZA202213710B (en) 2024-04-24
EP4112648A1 (en) 2023-01-04
JP2023522795A (ja) 2023-05-31
US20230233665A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
BR112022021758A2 (pt) Proteína e vacina contra infecção pelo sars-cov-2
CR20230104A (es) Compuestos y métodos para el tratamiento de infecciones virales
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
ES2186811T3 (es) Derivados de feniltiazol con propiedades anti-virus herpes.
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
BR0013771A (pt) Composto, métodos de tratamento de uma infecção viral em um mamìfero, de inibir a transcriptase reversa do hiv, e de prevenção da infecção do hiv ou de tratar a infecção do hiv, uso de um composto, e, composição farmacêutica
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
DE60036961D1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
NO20091441L (no) Rekonstituerte surfaktanter med forbedrede egenskaper
MX2023004188A (es) Compuestos fosfolipidos y usos de estos.
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
ZA202211004B (en) 3clpro-targeting phillyrin, derivative thereof, and use thereof against novel coronavirus
AR004326A1 (es) Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista.
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
CO2021007006A2 (es) Moduladores de la expresión de irf5
BR112020004935A2 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
BR0010084A (pt) Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
BR112021018205A2 (pt) Pequenos agentes bloqueadores de liberação.
BR112021018222A2 (pt) Composição